MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
0.5596
-0.0014
-0.25%
Opening 14:01 12/06 EST
OPEN
0.5680
PREV CLOSE
0.5610
HIGH
0.5890
LOW
0.5550
VOLUME
623.67K
TURNOVER
0
52 WEEK HIGH
2.350
52 WEEK LOW
0.4200
MARKET CAP
127.10M
P/E (TTM)
-1.1437
1D
5D
1M
3M
1Y
5Y
Adaptimmune Therapeutics Plc: Current report
Press release · 8h ago
Weekly Report: what happened at ADAP last week (1127-1201)?
Weekly Report · 2d ago
Buy Rating Affirmed for Adaptimmune on Strong Pipeline Developments and Market Expansion Potential
TipRanks · 5d ago
Adaptimmune Therapeutics Plc: Securities to be offered to employees in employee benefit plans
Press release · 5d ago
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
NASDAQ · 6d ago
Weekly Report: what happened at ADAP last week (1120-1124)?
Weekly Report · 11/27 09:31
Weekly Report: what happened at ADAP last week (1113-1117)?
Weekly Report · 11/20 09:31
Adaptimmune Therapeutics Plc: Current report
Press release · 11/14 14:19
More
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Webull offers Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ: ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.